Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Kezar Life Sciences
Biotech
Kezar suspends key lupus study after 4 deaths
The voluntary hold comes after Kezar restructured last year to in a bid to support its lupus and hepatitis candidate zetomipzomib.
Zoey Becker
Sep 30, 2024 11:23am
Kezar drops solid tumor yet to prove its worth in phase 1 trial
Aug 14, 2024 5:09am
Lilly picks new head of diabetes, obesity unit—Chutes & Ladders
Oct 6, 2023 9:30am
Kezar offloads 41% of staff, CEO to keep lupus candidate affloat
Oct 4, 2023 7:40am
Inventiva, Kezar sell Asian rights to NASH and autoimmune assets
Sep 21, 2023 9:00am
Agios replaces CEO after recent FDA nod—Chutes & Ladders
Jul 15, 2022 9:30am
